In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional EPO Deals: Large vs. Small Molecules

Executive Summary

Two recent deals in the EPO space by Astellas and Takeda show how Japanese pharma is competing at top level for product rights outside its domestic market, and illustrate the heady terms that next-generation EPO candidates command. They're also another sign that regional dealmaking is back.
Advertisement

Related Content

Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Why EPO Matters
Why EPO Matters
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit
Why EPO Matters
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel